The Egypt pharmaceutical market is the largest in the Middle East and Africa by volume, and for any export or business development lead, it looks like the obvious next target.
That instinct is where many suppliers go wrong.

Treat Egypt like Kenya or Uzbekistan, and ship finished products in, and you meet a market where local factories already make roughly nine in ten of the medicines it uses, prices are set by a regulator, and recent currency shocks have thinned importers’ margins.
The potential exists; however, many steps remain.
More than 90% of the raw materials[1] and active pharmaceutical ingredients (APIs) used by Egyptian pharmaceutical manufacturers are imported into the country.
As a result, the country functions as a primary importer of raw materials/ingredients rather than finished products.
Therefore, if you are responsible for strategic planning, exporting or selling APIs, then the question of “whether Egypt has potential” has been answered.
Instead, the focus should be on identifying the best way to enter the Egyptian pharmaceutical industry based on the current industry structure.
In this document, we will discuss the structure of the Egyptian pharmaceutical industry, the four entry options available, as well as the registration/pricing issues associated with each option.
The Prize – and Why Egypt Is Different
Africa’s largest pharmaceutical market
Egypt is one of the most valuable markets in the African Region.

It is valued at about US$5 billion,[2] which ranks it second in the Middle East and Africa by value, behind Saudi Arabia, and first by volume.
It serves a population of roughly 109.5 million people,[3] and the same source credits Egypt with the region’s largest manufacturing base, nearly 30% of the MENA market.[1]
Other commercial estimates run higher, so treat any single value as indicative; definitions, reporting years and market scope differ.
What counts in terms of strategy is not the total amount of money reported as a “headline” figure; rather, it’s about what part of that total goes to whom.
In other words, if you’re a foreign company selling goods into Egypt, you will have to determine if your market is based upon imported finished goods or on manufacturing them locally.
Since Egypt is an example of the latter type of market, the rest of this chapter will illustrate why this distinction must inform each subsequent choice you make regarding products, partners and prices.
The distinction that changes the strategy
Size alone does not explain the entry logic. Structure does.
Egypt’s regulator reports a self-sufficiency rate of 91.3% in finished medicines,[4] and the Egyptian pharmaceutical industry now counts 183 pharmaceutical factories.[5]
Yet the Egyptian Drug Authority (EDA) head has said the country imports over 90% of its raw materials and active pharmaceutical ingredients,[1] while an industry executive puts local API production at only 8-10% of domestic needs.[1]
In simple terms, what is most needed in Egypt is not mainly finished medicines; rather, it is the raw materials (the active ingredients) used to produce those finished medicines.
This is why the ideal approach to entering the Egyptian pharmaceutical market is different from a market that relies on importing finished products and why raw materials for medicine production, API exports from India and pharmaceutical intermediate products require more attention than submitting yet another application to register a finished pack.
Actiza’s portfolio of APIs and intermediate products falls directly into that upper level of the supply chain, and our guide to pharmaceutical exports to Africa and Latin America provides a broader view of the regional market.
| Dimension | Egypt | Typical import-dependent market (e.g., Kenya, Uzbekistan) |
| Finished-medicine supply | Roughly 91 – 94% made locally (estimates vary by basis) | Majority imported |
| API supply | Over 90% imported; local production covers approximately 8 -10% | Imported, often through imported finished products |
| Local industry | Africa’s largest; 180+ factories; major exporter | Small or emerging |
| Best entry for a foreign supplier | API supply, technology transfer, toll manufacturing, and licensing | Finished formulations imports and registration |
Why a ‘Just Import Finished Products’ Plan Fails Here
A simple strategy is to produce the final product and bring it into the country. This model does not work well in Egypt.
Most of the market is supplied by existing Egyptian producers who have scale, local connections, and solid support from their home government.
You cannot control your own pricing: The Egyptian Drug Authority (EDA) Pricing Committee determines what you can charge for your product; therefore, as an importer, you will have a higher landed cost than a local producer operating within the same price band.
Additionally, the foreign exchange issue further exacerbates the problem, as imported goods are purchased using hard currency, whereas your revenue will come in Egyptian pounds.
The result is thin margins and a high competitive wall in commodity generics, the segment the local industry already serves well.
A supplier who arrives with a standard oral solid dosage product is effectively asking regulators and buyers to prefer a more expensive import over a locally made equivalent.
The fact that there are some finished-product imports that cannot compete in the Egyptian marketplace does not mean that all finished-product imports are dead on arrival.
In addition to importing many of its basic medical needs, Egypt continues to import most of its raw materials APIs, and advanced medical products such as oncology drugs, immunotherapy drugs, biotech drugs, and other specialty drugs.
However, these types of products have not been developed within the country yet.
When entering the Egyptian marketplace with finished formulations, it would appear to be most beneficial if you can demonstrate a true shortage or need in the Egyptian marketplace rather than assume that one exists.
The Two Forces That Punish the Wrong Entry
Price caps meet a currency collapse
When the Egyptian pound was floated in March 2024, the dollar rose from about EGP 30.9 to about EGP 47.97.[6]
That is a rise of about 55% in the dollar’s price, or a fall of roughly 36% in the pound’s dollar value.
Manufacturers faced sharply higher input costs while regulated prices adjusted slowly.

This drop resulted in significantly increased costs of inputs for manufacturers.
An industry representative put the sector’s imported share at about 95% of raw materials,[6] and one industry voice reported shortages of 20-40% of drug trade names[6] at the peak.
Additionally, importers stated that some shipments were delayed at ports due to a shortage of foreign currency.
Therefore, foreign currency availability became both a source of risk relating to costs and a source of risk relating to supply.
Headline growth needs careful reading too. One source reports the market reached EGP 307 billion in 2024, up 42% year on year.[2]
Measured in a currency that lost a large share of its value, that is nominal growth.
It should not be read as a 42% rise in volume.
The local-production wall – and the regional price shadow
A second factor is structural. In addition to competing with a large national pharmaceutical industry, you also have to submit each of your final products to a different price review.
The Pricing Committee evaluates your application after a scientific evaluation has been conducted.
They will then compare your proposed prices to those in reference countries (such as Saudi Arabia, the United Arab Emirates, Jordan, Tunisia and Morocco) and to local therapeutic substitutes.
This same source reports that the Pricing Committee is recognized for having strong negotiating positions and low pricing.
In addition to the national shadow, there is a regional shadow. Some neighboring countries may use Egyptian prices as a base for setting their own prices.
If Egyptian prices are low, then you will have to set your prices lower than you would if Egypt had higher prices.
A supplier has three options when deciding how to proceed with their business model: they can export their active pharmaceutical ingredients (APIs), license out their products to other companies, or import completed medication from another country.
The result of making this choice is obvious. Importing completed medications will subject them to all of the price fluctuations and exchange rate risks that come with doing international commerce.
However, exporting APIs and/or licensing out their products would allow them to take advantage of significantly fewer risks.
The Four Entry Routes – Matched to Egypt’s Reality
The right entry follows from the market structure: lead with what Egypt most needs, which is APIs, and build toward deeper local partnership over time.
These four routes are not mutually exclusive. An Indian supplier can begin with API exports and later add licensing or local partnerships.

Route 1 – Supply APIs to Egypt’s local industry (the primary opportunity)
Register and supply APIs to local factories. With over 90% of raw materials and APIs imported[1] and regulators seeking reliable sources, this is the most natural opening.
Because Egyptian manufacturers also export, one API line may serve demand beyond Egypt, though that depends on each customer’s export mix.
Route 2 – Tech transfer, toll and contract manufacturing, and licensing
Partner with an Egyptian factory. License a product for manufacturing locally; provide raw materials (API) and technical expertise; or have a contract manufacturing agreement (toll or pharma).
The EDA’s goal of “localizing” is met by this type of partnership. Their stated program plans to localize approximately 400 APIs.[7]
The first step will focus on the top 50 most imported APIs. Therefore, as a partner, you are supporting the localization of APIs in Egypt, not being a victim of it.
Route 3 – Selective finished-formulation import for genuine gaps
Import finished products only where Egypt does not yet make them, such as oncology, biologics and specialty therapies.
Avoid commodity generics, where price caps and local competition bite hardest.
Route 4 – Local manufacturing or joint-venture investment
Companies that want to engage in long-term business, tender-exposed business, or hub-based business should either set up or partner with a facility in Egypt.
There are several benefits to doing so, including possible incentives and access to re-exports.
However, these depend on the specific project, the investment framework and the applicable trade agreement.
Therefore, you should check each possibility separately.
Additionally, setting up a local facility involves higher capital costs than some of the other methods listed above.
It also exposes you to price risks on the final product.
As such, establishing a local facility may be better suited for companies that have already established themselves in the market via previous API business or partnership business.
Generally speaking, many suppliers will follow the sequence of the methods outlined above.
Establishing an API relationship provides opportunities to establish relationships with regulators and familiarize yourself with regulatory processes.
This makes evaluating whether or not to enter into a licensing arrangement or form a joint venture with a reliable partner much easier.
| Entry route | What it involves | Best for | Key consideration |
| API supply | Register and supply APIs to local factories | High-volume generic and chronic-disease APIs | Primary opportunity; local re-exports may multiply demand |
| Technology transfer / toll / licensing | License products and supply APIs or know-how to a local manufacturer | Products on the EDA localisation list | Partner with localisation rather than compete against it |
| Selective finished imports | Register and import finished formulations | Oncology, biologics, and specialty gaps | Price caps and FX pressures; target genuine gaps |
| Local manufacturing / JV | Establish or partner in an Egyptian facility | Long-term, tender-exposed, and regional-hub businesses | High capital requirements; potential incentives and re-export opportunities |
The EDA Registration Pathway
Egypt pharmaceutical registration follows the steps below, which describe the finished-medicine pathway.
API suppliers usually engage through the local manufacturer’s dossier, so confirm API-specific requirements with the EDA or local counsel before filing.
Step 1 – Appoint an Egyptian Marketing Authorization Holder / local representative
Foreign manufacturers have to select an Egyptian company, either as a distributor or as an agent, to act on behalf of the local manufacturer.
The Egyptian company is responsible for being registered, importing products, and providing pharmacovigilance services.
If you want to sell your API, find out which local manufacturer is going to utilize your product.
Step 2 – Set the regulatory and commercial strategy
Select your route first (either API supply, toll, local license, or imported finished product).
Different types of licenses require varying amounts of documentation; therefore, select your license prior to beginning the process of assembling the required documentation.
Step 3: Compile the CTD/eCTD dossier
Prepare a CTD, verifying that you have confirmed with the EDA that you are preparing the CTD in accordance with the current EDA submission format.
GMP documentation, quality control and manufacturing (CMC) data, and, when required, a Certificate of Pharmaceutical Product (CPP) should be included.
Labels should be prepared in both Arabic and English; however, it is the Arabic label that will be legally binding.

Step 4 – Import samples and complete laboratory testing
The samples from the product are sent to EDA-linked labs. If they fail, they are rejected.
Therefore, the sample batches that are being tested need to be representative of the same quality as those products sold commercially.
Step 5 – Scientific assessment and (for some) GMP inspection
The EDA evaluates products for quality, safety, and effectiveness.
Although it accepts WHO prequalification and inspections by regulatory agencies with strict standards, the EDA frequently conducts its own inspections.
In December 2024, the Egyptian Drug Authority achieved WHO Maturity Level 3.
Step 6 – Pricing approval – the longest phase
The pricing application will be submitted to the Pricing Committee.
According to one specialised guide, this process takes from two to six months, and then an additional four to eight weeks are required for approval by the Supreme Council.
Additionally, the same guide reports that it can take six to twelve months for the scientific evaluation to occur, meaning that the pricing process is not necessarily the most time-consuming stage in terms of duration.
Rather, pricing is a distinct, heavily negotiated process that occurs after assessment; delays in completing this stage will result in an increase in the overall 12-24 month timeframe; therefore, make sure you take this into account when planning your schedule.
Step 7 – Market authorization and import
Upon authorization, the EDA will issue an authorization; then obtain import permits and list the product.
Keep your budget real: specialists estimate that registration takes from 12 to 24 months, depending upon the type of product being registered, the quality of the dossier submitted, and how many times the authority asks questions about it.
The Pricing and Money Reality
It is important to understand the pricing mechanism to separate a sustainable entry from a loss-making one.
| Dimension | How it works | Implication for your entry |
| Pricing mechanism | The EDA Pricing Committee sets the maximum selling price, benchmarked against reference-country prices under external reference pricing; cost-plus was the older method | Potentially thin regulated margins on finished products |
| Pricing step | Separate pricing review, about two to six months, then Supreme Council approval | A distinct, negotiation-heavy step that can lengthen the timeline |
| Currency / FX | The dollar rose from about EGP 30.9 to 47.97 in March 2024; about 95% of raw materials are imported; approved prices lagged | Margin pressure and possible supply disruptions |
The route choice follows from this. API supply and technology-transfer revenue come from a manufacturer’s purchase or licence terms rather than from a regulated shelf price, so the margin does not depend directly on the Pricing Committee outcome.
If the manufacturer re-exports, part of Egypt’s pricing constraint stays with the finished product it sells, not with the ingredient you supply.
This is a commercial argument, not a legal exemption: APIs still face registration, customs and compliance obligations, and your customer’s margin pressure can flow back into your price negotiations.
Reference-country comparison matters most. Because the committee benchmarks against other markets, your Egyptian price is never set in isolation, and pricing decisions in one country can echo in others.
Currency matters just as much: a price approved today may not cover tomorrow’s hard-currency cost if the pound weakens again. Plan for both before you commit inventory or a dossier budget.
The table suggests which way to go when selecting products.
When a final product moves into a different price group than what was initially determined by the company, it will be compared to other regions’ prices.
It will be susceptible to fluctuations in currency exchange rates.
Evaluate each potential product based on three criteria: what is the highest possible selling price; what are the estimated hard-currency costs of importing the product into Egypt; and could a low-priced product sold in Egypt negatively impact sales in other areas where your company operates?
Where India Fits: the Multiplier Market
Indian Active Pharmaceutical Ingredient (API) suppliers provide cost-effective scale, competitive prices, and international trade knowledge.
There are over 500 different APIs manufactured in India; it is the world’s third-largest API manufacturer with an 8% market share of the world’s API industry.
It provides approximately 20% of the world’s exported generic drugs.

In addition, many of the Indian suppliers are accustomed to providing the required documentation to both their customers and regulatory agencies.
However, this does not mean that India will always be the best option for every type of API.
Each decision to award a contract to a specific supplier is based on the price of the product, the quality of previous products delivered by that supplier, how reliable they were at delivering products on time, and what level of regulatory support they offered.
Localisation deserves an honest reading. Egypt’s regulator is pushing to produce more ingredients at home, reporting 155 APIs localised between 2023 and 2025[8] and a wider ambition covering about 400 APIs.
Some of that volume will shift from imports to local production, particularly for the most heavily imported ingredients, and suppliers should plan for it rather than ignore it.
The same article frames the challenge as competing with producers in India and China on scale, and pharmaceutical exports of about US$1.3 billion by end-2025[8] show that local formulators export too.
For a supplier, localisation can mean fewer finished-product imports, continued demand for imported ingredients, and more partnership, investment and compliance conversations.
The strategic fit follows. A supplier that leads with APIs and technology partnership, rather than finished-product import, is aligned with Egypt’s direction and less exposed to price-cap and currency pressure.
It is also positioned to supply manufacturers who serve wider regional demand, though no outcome is guaranteed.
What This Means for a Quality-Assured API Partner
Egypt’s profile, with strong local formulation, heavy reliance on imported ingredients and tightly priced finished products, rewards a supplier that enters as an API and partnership-led player.
Actiza Pharmaceutical will help you with these terms.
Its WHO-GMP certified manufacturing and ISO-certified quality systems support quality-assured supply, and it cites 550+ ready dossiers and regulatory support for 40+ countries.
It offers third-party and contract manufacturing, and its range covers APIs, advanced intermediates and finished formulations that may suit genuine specialty gaps.
Any technology transfer arrangement would be scoped with the Egyptian partner case by case, and product-level fit and EDA requirements should be confirmed during discussions.
The relevant strengths for this market are documentation readiness, consistent quality and a portfolio that matches high-volume chronic and essential categories.
Buyers will still judge each product on price, batch consistency and regulatory support, so the useful first step is a technical conversation about specific ingredients rather than a general introduction.
If your team is evaluating Egypt, start with the ingredient list your target manufacturers use, then work backwards to the right route.
Frequently Asked Questions
Q1. How much of Egypt’s medicine is made locally versus imported?
Estimates vary by basis. Egypt reports 91.3% self-sufficiency in finished medicines, and the EDA chairman has cited 92-94% local coverage of essential and chronic medicines.
The imported share therefore sits in single digits to low double digits for finished products, but the ingredients behind them are mostly imported.
Q2. Why is Egypt a strong market for Indian API suppliers specifically?
Local factories need ingredients at scale, and India makes more than 500 APIs at competitive cost.
Egyptian regulators acknowledge that matching Indian and Chinese scale is the hard part of localisation. Fit still depends on product, price and quality.
Q3. Who regulates drug registration in Egypt and how long does it take?
The Egyptian Drug Authority regulates registration. Specialists report 12 to 24 months in practice, and one guide gives 12-18 months for generics and 18-24 months for new chemical entities.
Timelines depend on category, dossier quality and inspections.
Q4. Why are drug prices and shortages such a challenge in Egypt?
Maximum prices are regulated while industry sources report that about 95% of raw materials are imported.
When the dollar rose about 55% against the pound in March 2024, costs outran approved prices and shortages followed.
Q5. What is the best way for an Indian supplier to enter the Egyptian market?
Lead with APIs for local manufacturers, add technology transfer, toll or licensing where products fit EDA localisation priorities, and import finished products only for genuine gaps.
Confirm pricing, currency and registration requirements first.
Conclusion
The Egypt pharmaceutical market is a major prize, but it is won differently from almost anywhere else.
Egypt already makes most of its finished medicines and imports most of its active ingredients, so the exporters who succeed are rarely those shipping finished products into a price-regulated, currency-stressed market.
They supply APIs and partner in the local manufacturing Egypt is building.
Lead with APIs where commercially and regulatorily appropriate, align with localisation rather than resisting it, reserve finished-product imports for genuine gaps, and test pricing, currency, registration and regional effects before committing.
Egypt may also serve as a manufacturing and re-export hub for wider regional demand, which is why a well-chosen partner can matter more than a single order.
Entered on those terms, Egypt is not just a market.
It can be a multiplier. If you are exploring an Egypt or North Africa API partnership, contact Actiza’s team to discuss your target products and documentation needs.
- https://enterpriseam.com/egypt/inside_industry/the-localization-push-a-new-formula-for-the-egyptian-pharma-industry/
- https://www.bionixus.com/blog/healthcare-overview-egypt-market-2026
- https://www.egypttoday.com/Article/1/149579/Egypt%E2%80%99s-domestic-population-reaches-109-5-Million-CAPMAS
- https://enterpriseam.com/egypt/2026/01/18/arab-api-kicks-off-construction-on-factory-to-address-90-reliance-on-pharma-raw-material-imports-2/
- https://businessmonthlyeg.com/qa-eda-chairman-on-egypts-pharmaceutical-manufacturing-growth-investment-and-exports/
- https://english.ahram.org.eg/NewsContent/3/12/527162/Business/Economy/Pharmaceutical-market-in-Egypt-Severe-shortage-vs-.aspx
- https://meobserver.news/life-style/health-medicine/2026/08/16/egypt-targets-pharmaceutical-raw-materials-after-decade-of-manufacturing-growth/
- https://businessmonthlyeg.com/qa-eda-chairman-on-egypts-pharmaceutical-manufacturing-growth-investment-and-exports/
